U.S. markets open in 3 hours 50 minutes
  • S&P Futures

    4,469.75
    -4.50 (-0.10%)
     
  • Dow Futures

    34,742.00
    -7.00 (-0.02%)
     
  • Nasdaq Futures

    15,500.50
    -17.25 (-0.11%)
     
  • Russell 2000 Futures

    2,223.90
    -4.00 (-0.18%)
     
  • Crude Oil

    71.99
    -0.62 (-0.85%)
     
  • Gold

    1,765.40
    +8.70 (+0.50%)
     
  • Silver

    23.08
    +0.29 (+1.25%)
     
  • EUR/USD

    1.1783
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.84
    +0.66 (+3.63%)
     
  • GBP/USD

    1.3794
    -0.0003 (-0.02%)
     
  • USD/JPY

    109.9730
    +0.2550 (+0.23%)
     
  • BTC-USD

    47,811.31
    -373.23 (-0.77%)
     
  • CMC Crypto 200

    1,220.43
    -12.86 (-1.04%)
     
  • FTSE 100

    7,036.44
    +8.96 (+0.13%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

StemCells receives FDA authorization of IND for spinal cord injury

StemCells announced that the FDA has authorized the company's Investigational New Drug, or IND, application for clinical testing of the company's proprietary HuCNS-SC human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada.